Protocol Ledger

NCT04808505 · Phase III · RECRUITING

A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18

Interventional Phase III clinical trial protocol NCT04808505 sponsored by Amicus Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-07-18 Enrollment: 36 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04808505
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)36 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04808505
Protocol FieldVerified Registry Value
NCT IdentifierNCT04808505
Consolidated Lead SponsorAmicus Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment36 participants (ESTIMATED)
Registered Start Date2023-07-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI